[1] Shi YW, YangnRX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol, 2021, 27(26):3971-3983. [2] Jothimani D, Rela M,Kamath PS. Liver cirrhosis and portal hypertension: how to deal with esophageal varices? Med Clin North Am, 2023, 107(3):491-504. [3] Rockey DC, Alsawas M, Duarte-Rojo A,et al. Noninvasive liver disease assessment to identify portal hypertension: systematic and narrative reviews supporting the AASLD practice guideline. Hepatology, 2025, 81(3):1086-1104. [4] Hamasaki M, Araki T, Tamada D,et al. Four-dimensional flow magnetic resonance imaging for assessment of hemodynamic changes in the portal venous system before and after balloon-occluded retrograde transvenous obliteration: a pilot feasibility study. Acta Radiol, 2023, 64(4):1462-1468. [5] Palaniyappan N, Cox E, Bradley C,et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol, 2016, 65(6):1131-1139. [6] 中华预防医学会,中国疾病预防控制中心免疫规划中心.中国成人乙型肝炎免疫预防技术指南.中华流行病学杂志,2011,32(12):1199-1203. [7] 中华医学会肝病学分会.肝硬化诊治指南.中华肝脏病杂志,2019,27(11):846-865. [8] 高晓婷,高鑫,刘艳莉,等. 常规超声与超声造影评估肝硬化门静脉高压症患者TIPS术后支架功能价值分析. 实用肝脏病杂志,2025,28(4):589-592. [9] Liu C, Chen S, Yan X, et al. Diagnostic value of portal vein velocity for portal hypertension in patients with hepatitis B virus-related cirrhosis. Curr Med Imaging, 2021, 17(11):1363-1368. [10] Garcia-Guix M, Ardevol A, Sapena V,et al. Influence of further decompensation on survival across clinical stages of decompensated cirrhosis: the role of portal hypertension and HVPG changes. Liver Int, 2024, 44(8):1971-1989. [11] Yoo JJ, Kim SG. The rise of non-invasive tools in the diagnosis of portal hypertension:validation of the Baveno VII consensus. Clin Mol Hepatol, 2023, 29(1):102-104. [12] 穆玉娟,吴斐斐,陈莹.磁共振增强T1 mapping和IVIM-DWI技术评估乙型肝炎肝硬化患者肝脏储备功能价值研究.实用肝脏病杂志,2024,27(1):68-71. [13] Edelman RR, Ozturk O, Pursnani A,et al. Equilibrium phase contrast-enhanced magnetic resonance angiography of the thoracic aorta and heart using balanced T1 relaxation-enhanced steady-state. J Cardiovasc Magn Reson, 2024, 26(2):101046. [14] Li J, Lu X, Zhu Z,et al. Head-to-head comparison of magnetic resonance elastography-based liver stiffness, fat fraction, and T1 relaxation time in identifying at-risk NASH. Hepatology, 2023, 78(4):1200-1208. [15] Li Q, Chen T, Shi N,et al. Quantitative evaluation of hepatic fibrosis by fibro scan and Gd-EOB-DTPA-enhanced T1 mapping magnetic resonance imaging in chronic hepatitis B. Abdom Radiol (NY), 2022, 47(2):684-692. [16] 吕天富,南琼.经颈静脉肝内门体分流术治疗肝硬化门静脉高压症患者抗凝治疗研究进展.实用肝脏病杂志,2025,28(2):165-168. [17] Liu J, Li Q, Shi N,et al. Preliminary clinical study of the safety of hepatectomy predicted by gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced T1 mapping magnetic resonance imaging. JGH Open, 2021, 5(3):382-389. [18] Nauffal V, Klarqvist MDR, Hill MC,et al. Noninvasive assessment of organ-specific and shared pathways in multi-organ fibrosis using T1 mapping. Nat Med, 2024, 30(6):1749-1760. [19] Obmann VC, Berzigotti A, Catucci D,et al. T1 mapping of the liver and the spleen in patients with liver fibrosis-does normalization to the blood pool increase the predictive value? Eur Radiol, 2021, 31(6):4308-4318. [20] Jiang Y, Yin P, Wang Y,et al. Rapid liver tissue characterization using simultaneous multi-relaxation-time imaging: a comparative study with conventional magnetic resonance imaging. Quant Imaging Med Surg, 2025,15(5):4400-4413. |